Di Yi Cai Jing·2026-02-19 06:58Group 1 - The core point of the article highlights the competitive landscape between Eli Lilly and its main competitor Novo Nordisk in the development of new weight loss therapies, particularly focusing on the potential of Eli Lilly's drug tirzepatide for treating obesity in patients with autoimmune diseases [1] - A late-stage study involving 274 psoriasis patients showed that the combination of tirzepatide and the existing biologic drug, etanercept, resulted in better outcomes than etanercept alone, with approximately 27.1% of patients achieving complete psoriasis clearance and a 10% weight reduction after 36 weeks [1] - The study indicates the potential of weight loss drugs in treating obesity-related comorbidities, as most obese patients have at least one weight-related comorbidity [1] Group 2 - The expansion of new indications for tirzepatide means a broader patient base, as it recently received approval from the National Medical Products Administration in China for use in adult patients with type 2 diabetes (T2DM) as a monotherapy [2] - In the European market, Novo Nordisk's weight loss drug semaglutide at a higher dosage of 7.2mg has also received approval, providing more treatment options for doctors and patients [2] - Eli Lilly is preparing for competition in the oral weight loss drug market, with pre-launch inventory for its oral weight loss medication reaching $1.5 billion, a significant increase from $550 million in the same period last year [2]